# EDGAR Filing Document

**Accession Number:** 0001818331
**File Stem:** 0001818331-25-000117
**Filing Date:** 2025-9
**Character Count:** 7155
**Document Hash:** 024fe4653850c71bd438e7cf378ce811
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001818331-25-000117.hdr.sgml**: 20250905

**ACCESSION NUMBER**: 0001818331-25-000117

**CONFORMED SUBMISSION TYPE**: POS AM

**PUBLIC DOCUMENT COUNT**: 2

**REFERENCES 429**: 333-267112

**FILED AS OF DATE**: 20250905

**DATE AS OF CHANGE**: 20250905

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GeneDx Holdings Corp.
- **CENTRAL INDEX KEY:** 0001818331
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-HEALTH SERVICES [8000]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 851966622
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** POS AM
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-267112
- **FILM NUMBER:** 251294993

**BUSINESS ADDRESS:**
- **STREET 1:** 333 LUDLOW STREET
- **STREET 2:** NORTH TOWER, 6TH FLOOR
- **CITY:** STAMFORD
- **STATE:** CT
- **ZIP:** 06902
- **BUSINESS PHONE:** 888-729-1206

**MAIL ADDRESS:**
- **STREET 1:** 333 LUDLOW STREET
- **STREET 2:** NORTH TOWER, 6TH FLOOR
- **CITY:** STAMFORD
- **STATE:** CT
- **ZIP:** 06902

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Sema4 Holdings Corp.
- **DATE OF NAME CHANGE:** 20210721

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CM Life Sciences, Inc.
- **DATE OF NAME CHANGE:** 20200715

**As filed with the Securities and Exchange Commission on September 5, 2025** 

**Registration No. 333-267112**

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**POST-EFFECTIVE AMENDMENT NO. 1 TO** 

**FORM S-3** 

**REGISTRATION STATEMENT** 

***UNDER***

***THE SECURITIES ACT OF 1933***

![image_0.jpg](image_0.jpg)

**GeneDx Holdings Corp.** 

**(Exact name of Registrant as specified in its charter)** 

---

| | |
|:---|:---|
| **Delaware** | **85-1966622** |
| **(State or other jurisdiction of**<br>**incorporation or organization)** | **(I.R.S. Employer**<br>**Identification Number)** |

---

**333 Ludlow Street, North Tower; 6th Floor** 

**Stamford, Connecticut 06902** 

**(888) 729-1206** 

**(Address and telephone number of Registrant's principal executive offices)** 

**Katherine Stueland**

**Chief Executive Officer** 

**333 Ludlow Street, North Tower, 6th Floor**

**Stamford, Connecticut 06902** 

**(888) 729-1206**

**(Name, address, and telephone number of agent for service)** 

------

---

| | |
|:---|:---|
| **Copies to:** | **Copies to:** |
| **Ethan Skerry**<br>**Per B. Chilstrom**<br>**Fenwick & West LLP**<br>**902 Broadway**<br>**New York, New York 10010**<br>**(212) 430-2600** | **Kevin Feeley**<br>**Chief Financial Officer<br>GeneDx Holdings Corp.<br>333 Ludlow Street, North Tower, 6th Floor<br>Stamford, Connecticut 06902<br>(888) 729-1206** |

---

**Approximate date of commencement of proposed sale to the public:** Not applicable.

If only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box: ☐

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box: ☐

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering: ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering: ☐

If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box: ☐

If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box: ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act:

---

| | | | |
|:---|:---|:---|:---|
| Large Accelerated Filer | ☐ | Accelerated Filer | ☒ |
| Non-accelerated Filer | ☐ | Smaller reporting company | ☐ |
| | | Emerging growth company | ☒ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act.☐

------

**DEREGISTRATION OF UNSOLD SECURITIES** 

This Post-Effective Amendment No. 1 to Form S-3 relates to the Registration Statement on Form S-3 (333-267112), filed with the Securities and Exchange Commission on August 26, 2022 (the "<u>Registration Statement</u>") by GeneDx Holdings Corp., a Delaware corporation (the "<u>Registrant</u>"). The Registration Statement registered the sale of up to $300,000,000 of the Registrant's securities.

Prior to third anniversary of the initial effective date of the Registration Statement, the Registrant had offered and sold $225,064,750 of the Registrant's securities pursuant to the Registration Statement, with $74,935,250 of the Registrant's securities (the "<u>Remaining Unsold Securities</u>") remaining unsold as of such anniversary. In accordance with an undertaking made by the Registrant in the Registration Statement to remove from registration, by means of a post-effective amendment, any of the securities that had been registered for issuance that remain unsold at the termination of the offering, the Registrant hereby removes from registration the Remaining Unsold Securities registered under the Registration Statement as of the date hereof.

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this Post-Effective Amendment No.1 to the Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Stamford, State of Connecticut, on the 5th day of September, 2025.

---

| | |
|:---|:---|
| **GENEDX HOLDINGS CORP.** | **GENEDX HOLDINGS CORP.** |
| By: | */s/ Katherine Stueland* |
| Name: | Katherine Stueland |
| Title: | Chief Executive Officer |

---

No other person is required to sign this Post-Effective Amendment in reliance upon Rule 478 under the Securities Act of 1933, as amended.

<br>